Granisetron Labormed (Granisetron)

Granisetron Labormed is indicated for the prevention of nausea and vomiting in specific clinical settings.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV).
• Prevention of postoperative nausea and vomiting (PONV).
• Adjunct therapy for radiation‑induced nausea.
• Use in patients receiving highly emetogenic chemotherapy.
• May be considered when other antiemetics are insufficient.

The safety profile of granisetron includes both common and less frequent adverse events.

Common

• Headache.
• Constipation.
• Diarrhea.
• Fatigue.
• Dizziness.

Serious

• Severe allergic reaction (anaphylaxis).
• Cardiac arrhythmia.
• Prolonged QT interval.
• Serotonin syndrome (rare).

When prescribing Granisetron Labormed, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess cardiac history, especially QT prolongation risk.
• Use caution in patients with electrolyte disturbances (e.g., low potassium or magnesium).
• Evaluate for known hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Consider renal or hepatic impairment when dosing.
• Avoid use during pregnancy unless benefit outweighs risk.
• Monitor for signs of serotonin syndrome if combined with serotonergic agents.

Granisetron may interact with other medications; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with other 5‑HT3 antagonists (e.g., ondansetron) due to additive effects.
• Co‑administration with drugs that significantly prolong QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution

• Serotonergic agents such as SSRIs, SNRIs, tramadol, or linezolid.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase granisetron levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce effectiveness.